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Abstract—In 76 patients with heart failure (HF) (New York Heart Association [NYHA] classes I through IV) and in 15
control subjects, cardiac angiotensin II (Ang II) generation and its relationship with left ventricular function were
investigated by measuring aorta–coronary sinus concentration gradients of endogenous angiotensins and in a part
of patients by studying 125I-labeled Ang I kinetics. Gene expression and cellular localization of the cardiac
renin-angiotensin system components, the density of AT1 and AT2 on membranes and isolated myocytes, and the
capacity of isolated myocytes for synthesizing the hypertrophying growth factors insulin-like growth factor-I (IGF-I)
and endothelin (ET)-1 were also investigated on 22 HF explanted hearts (NYHA classes III and IV) and 7 nonfailing
(NF) donor hearts. Ang II generation increased with progression of HF, and end-systolic wall stress was the only
independent predictor of Ang II formation. Angiotensinogen and angiotensin-converting enzyme mRNA levels were
elevated in HF hearts, whereas chymase levels were not, and mRNAs were almost exclusively expressed on nonmyocyte
cells. Ang II was immunohistochemically detectable both on myocytes and interstitial cells. Binding studies showed that
AT1 density on failing myocytes did not differ from that of NF myocytes, with preserved AT1/AT2 ratio. Conversely,
AT1 density was lower in failing membranes than in NF ones. Ang II induced IGF-I and ET-1 synthesis by isolated NF
myocytes, whereas failing myocytes were unable to respond to Ang II stimulation. This study demonstrates that (1) the
clinical course of HF is associated with progressive increase in cardiac Ang II formation, (2) AT1 density does not
change on failing myocytes, and (3) failing myocytes are unable to synthesize IGF-I and ET-1 in response to Ang II
stimulation. (Circ Res. 2001;88:961-968.)
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Conclusive evidence has been presented that all of thecomponents required for angiotensin II (Ang II) produc-
tion are present in the human heart1 and that Ang II is
continuously formed by cardiac tissues in healthy subjects.2
However, few studies have investigated the cardiac renin-
angiotensin system (RAS) in human hypertrophy and heart
failure (HF), as opposed to the large number of experimental
studies performed in cell culture systems and experimental
models (for studies, see Wollert and Drexler3). In human
explanted failing hearts, levels of angiotensin-converting
enzyme (ACE) mRNA,4 ACE activity, and ACE binding
sites5 have been found to be increased as compared with
control hearts. Levels of prorenin, renin, and ACE measured
with enzyme kinetics are higher in failing than in control
hearts.6 Although these studies provide important results,
demonstrating that cardiac RAS is activated in explanted
failing hearts, they do not provide information either about
cardiac Ang II production during the clinical course of HF or
about the relationship between Ang II and cardiac function.
Moreover, these studies do not answer the critical question as
to whether the enhanced cardiac expression of ACE actually
promotes an increased production of Ang II, because several
groups have challenged the notion that ACE is the major Ang
II–forming enzyme in the human heart.7,8 A second open
question is the identification of the cell types that actually
express Ang II receptors in the failing myocardium and
constitute the potential targets for Ang II receptor–mediated
effects. Several groups have investigated the density of Ang
II receptor subtypes in human failing hearts and have found a
reduction in AT1,5,9–11 either without changes in AT29,10 or
with an increase in them.5,11 However, these studies were
only performed on myocardial homogenates, and no informa-
tion is available on the regulation of Ang II receptor subtypes
on myocytes and nonmyocyte cells. A last but no less
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important question is the functional significance of cardiac
Ang II formation in myocardial hypertrophy and HF. Al-
though Ang II has been most frequently associated with both
experimental and human hypertrophy,12–14 the precise role of
Ang II in cardiac hypertrophy remains elusive,15,16 because
cardiac hypertrophy may develop in the presence of Ang II
generation inhibitors or AT1 blockade.17,18 Moreover, human
compensatory hypertrophy is associated with increased car-
diac formation of insulin-like growth factor-I (IGF-I) in
volume overload and endothelin (ET)-1 and IGF-I in pressure
overload, but not with cardiac Ang II.14
Thus, the functional significance of ACE mRNA and
increased ACE activity found in expanded hearts remains to
be clarified. Therefore, the present study was planned with
the following objectives: (1) to investigate whether and when
cardiac Ang II formation increases during the clinical course
of HF and its relationship with left ventricular function, (2) to
identify and examine the distribution of Ang II receptor
subtypes on myocytes and nonmyocyte cells from failing and
nonfailing (NF) myocardium, and (3) to study the relationship
between Ang II and the capacity of myocytes for producing
the hypertrophying growth factors IGF-I and ET-1.
Materials and Methods
We investigated 76 patients with HF due to dilated cardiomyopathy
(DCM, n536) or to ischemic cardiomyopathy (ICM, n540). Diag-
nosis of DCM or ICM was based on clinical and echocardiographic
examination, cardiac catheterization, and coronary angiography. HF
patients were classified into functional groups according to the New
York Heart Association (NYHA) classification (Table 1).
Patients with a recent history (,6 months) of myocardial infarc-
tion, a history of hypertension, echocardiographic evidence of valve
or congenital heart disease, or an inability to suspend ACE inhibitors
and diuretic treatment for 3 days were not considered for the study.
The control group was made up of 15 normotensive patients with
atypical chest pain in whom angiography and routine diagnostic
procedures did not reveal any abnormalities.
Cardiac specimens were obtained from 9 ICM and 13 DCM
patients in NYHA classes III (n510) and IV (n512), who underwent
cardiac transplantation, and 7 deceased donors with no history or
signs of heart disease, whose hearts could not be transplanted
because of surgical reasons or blood group incompatibility (NF
hearts) (Table 1).
The protocol of this study complies with the principles of the
Helsinki declaration. All patients gave their informed written consent
to participate and to have their heart and blood samples used for the
study. Echocardiographic and hemodynamic measurements were
performed prospectively, as previously described.14
Cardiac formation of endogenous angiotensins was estimated as
the aorta-coronary sinus gradient.14 Ang I and Ang II plasma
concentrations were measured by RIA after HPLC separation as
previously described.14 In 16 patients and 5 control subjects, the
study of 125I-labeled Ang I (125I-Ang I) kinetics was simultaneously
performed.14
Cardiomyocytes were isolated and membrane suspension was
prepared from a noninfarcted portion of left ventricle free wall.19 All
TABLE 1. Characteristics of Subjects Investigated
Control Subjects
n515
NF Hearts
n57
NYHA Class
I
n515
II
n514
III
n524
IV
n523
Age, years 60610 4465* 51617 5969 5967 59610
Sex (M/F) 13/2 5/2 10/5 13/1 21/3 17/6
Body surface area, m2 1.8960.10 1.8660.18 1.8860.19 1.8060.17 1.8560.21 1.8660.20
Treatments, No.
Digitalis 0 0 0 8 14 16
Furosemide 0 0 0 5 22 23
ACE inhibitors 0 0 8 11 24 23
Beta blockers 0 0 2 2 3 3
Etiology (ICM/DCM) z z z z z z 8/7 8/6 13/11 11/12
Left ventricular end-diastolic
diameter index, mm/m2
26.561.3 26.463.1 32.262.8† 32.762.8† 40.267.6† 42.465.6†
Left ventricular mass index, g/m2 109613 104618 175639† 180644† 234665† 251637†
Ejection fraction, % 6566 6163.9 54611† 44611† 24613† 1965†
Velocity of circumferential fiber
shortening, s21
1.1660.17 1.0960.23 1.0060.26 0.7860.22† 0.5360.09† 0.5160.13†
End-systolic stress, kdyn/cm2 7069 z z z 99618† 115632† 196657† 212651†
End-diastolic stress, kdyn/cm2 1463 z z z 2265† 32612† 64618† 74610†
Cardiac index, L/m23min21 3.2360.49 z z z 2.8060.26* 2.6160.34† 2.0860.46† 1.9160.41†
Left ventricular end-diastolic
pressure, mm Hg
8.361.5 z z z 13.664.1† 19.467.3† 27.166.6† 29.964.8†
Mean pulmonary artery
pressure, mm Hg
1163 z z z 1464 2066† 32612† 36615†
Pulmonary capillary wedge
pressure, mm Hg
763 z z z 864 1464† 2169† 23610†
PRA, ng/mL3hour21 0.8260.28 z z z 1.0960.81 1.6361.37* 3.5061.35† 4.4160.79†
*P,0.05, †P,0.01 vs control subjects.
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studies were performed on freshly isolated cells. Binding studies
were performed at equilibrium using 125I-Ang II (100 pmol/L, 2000
Ci/mmol, Amersham) and selective AT1 (Valsartan, a kind gift of Dr
V. Abbruscato, Novartis, Italy) or AT2 (PD-123319) antagonists.
mRNAs for renin, chymase, angiotensinogen (AGTN), ACE, AT1,
and AT2 were quantified by reverse transcriptase–polymerase chain
reaction (RT-PCR) using specific primers with GAPDH as internal
standard14 and were expressed as the percentage of the values
obtained in NF hearts.14 The in situ hybridization procedure was
performed using specific cDNA photobiotin-labeled (Vector)
probes.14 Myocardial cell types were identified by immunohisto-
chemical methods using specific monoclonal antibodies. The pres-
ence of Ang II in myocardium was detected with the immunohisto-
chemical method, using anti–Ang II rabbit antiserum (RIN 7002,
Peninsula Laboratory, Inc). The stimulating effects of Ang II (10
nmol/L) on ET-1, IGF-I, and platelet-derived growth factor (PDGF)
mRNA expression and peptide release by myocytes in vitro (100 000
myocytes/mL) were investigated in myocytes isolated from NF
(n54) and HF hearts (5 DCM and 4 ICM).
Data are mean6SD. Comparisons between groups were per-
formed using 1-way ANOVA. For multivariate reevaluation of
univariate correlations, the following were entered in a stepwise
multiple regression analysis as independent variables, considering
cardiac Ang II formation as a dependent variable: left ventricular
end-diastolic diameter index, relative wall thickness, left ventricular
mass index, left ventricular end-systolic volume index (LVESVI),
left ventricular end-diastolic volume index (LVEDVI), left ventric-
ular ejection fraction (LVEF), mean midwall velocity of circumfer-
ential fiber shortening (Vcf), end-systolic stress (ESS), end-diastolic
stress, left ventricular end-diastolic pressure, Vcf/ESS ratio, Vcf/
LVEDVI ratio, ESS/LVESVI ratio, and plasma renin activity (PRA).
An expanded Materials and Methods section can be found in an
online data supplement available at http://www.circresaha.org.
Results
Cardiac Ang II Formation and
Ventricular Function
Cardiac production of Ang II, as expressed by the mean
aorta-coronary sinus concentration gradient, was already
mildly but significantly increased in NYHA class I patients
and further increased with the worsening of the functional
class, with no differences being found between DCM and
ICM patients (Figure 1A).
The 125I-Ang I kinetics parameters are reported in Table 2.
Neither extraction of both radiolabeled angiotensins nor the
125I-Ang I–to–125I-Ang II conversion rate differed between
patients and control subjects (Table 2). Both Ang I and Ang
II formation by cardiac tissues were on average significantly
(P,0.01) higher in patients with mild HF (NYHA classes I
and II) than in control subjects and further increased in
patients with severe HF (NYHA classes III and IV; P,0.01).
The increased Ang I de novo formation in patients with mild
HF was mainly attributable to cardiac tissues, given that Ang
I formed by PRA during the transcardiac passage of blood
was not significantly different from that of control subjects
(Table 2). In patients with severe HF, the total amount of Ang I
formed was further increased versus mild HF with an increase in
the contribution also by PRA (Table 2). Cardiac Ang II forma-
Figure 1. A, Ang II aorta–coronary sinus gradient indexed by
coronary blood flow and cardiac mass (cardiac Ang II formation)
in control subjects (n) and HF patients (C indicates ICM; v,
DCM). Values under columns are mean6SD. *P,0.05 vs control
subjects. B, Relationship between cardiac Ang II formation and
ESS in HF patients.
TABLE 2. 125I-Ang I and 125I-Ang II Concentrations at Steady State During
125I-Ang I Infusion and Kinetics Parameters
Kinetics Parameters
Control Subjects
n55
Mild HF
n59
Severe HF
n57
125I-Ang I extraction, % 35.263.8 34.264.1 36.065.7
125I-Ang I to 125I-Ang II conversion rate, % 24.364.7 25.164.9 24.965.2
Ang I by PRA, pg/mL 1.160.4 1.660.7 5.662.2*†
Ang I by cardiac tissues, pg/mL 2.561.3 6.263.9* 7.765.8*†
Total amount of Ang I formed, pg/mL 3.661.5 7.866.9* 13.566.4*†
125I-Ang II extraction, % 26.862.8 27.961.9 27.862.2
Ang II by arterially delivered Ang I, pg/mL 1.160.6 1.260.7 1.460.8
Ang II by cardiac tissues, pg/mL 0.960.3 5.864.9* 10.365.9*†
Total amount of Ang II formed, pg/mL 2.160.8 7.263.4* 12.766.4*†
PRA, ng/mL3hour21 0.860.3 1.361.1* 4.060.6*†
Data are mean6SD.
*P,0.05 vs control subjects.
†P,0.05 vs mild HF.
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tion measured by 125I-Ang I kinetics was highly correlated with
the aorta-coronary sinus gradient (r50.89, P,0.001).
Ang II formation expressed by the aorta coronary sinus
gradient was usually increased in patients with reduced
LVEF, but it was found to be enhanced in a proportion of
patients (18 of 76, 23%) with only mildly reduced LVEF
($40%), provided that ESS was increased. Indeed, univariate
regression analysis showed that Ang II formation was nega-
tively correlated with left ventricular ejection fraction (LVEF,
r520.77, P,0.001) and with the various indexes of ventric-
ular contractility (Vcf, r520.72, P,0.001; Vcf/ESS,
r520.75, P,0.001; Vcf/LVEDVI, r520.72, P,0.001; and
ESS/LVESVI, r520.49, P,0.001). Conversely, it was pos-
itively correlated with ventricular systolic volume (LVESVI,
r50.74, P,0.001) and diastolic volume (LVEDVI, r50.62,
P,0.001). The multivariate stepwise analysis revealed that
ESS was the most predictive independent variable for Ang II
formation (r50.85, P,0.001) (Table 3, Figure 1B).
mRNA Expression of the Cardiac
RAS Components
RT-PCR Assay
AGTN, ACE, and chymase genes were expressed in the NF
hearts, whereas renin mRNA was not detectable (Figure 2).
AGTN and ACE mRNA levels were higher in failing than in
NF hearts, without any significant differences between ICM
and DCM hearts (Figure 2). Conversely, chymase mRNA
expression did not significantly differ in failing and NF hearts
(Figure 2).
Messengers for AT1 and AT2 were expressed in all myo-
cardial specimens. The AT1 mRNA levels were lower in
failing than in NF hearts (P,0.01) (Figure 2).
In Situ Hybridization
Negative and positive controls for in situ hybridization
showed that the hybridization signal was specific for mRNA
and that the mRNA in the hearts was intact). In NF hearts,
mRNA for AGTN and ACE was expressed only in trace
amounts. In the specimens from HF hearts, mRNA expres-
sion for AGTN and ACE was notably enhanced
and was expressed almost exclusively on nonmyocyte cells
(Figure 3).
Immunohistochemical Localization of Ang II
In NF hearts no immunostaining for Ang II was detected. In
HF hearts immunostaining for Ang II was detected in both
myocytes and interstitial cells (Figure 3).
Ang II Binding in NF and Failing Hearts
The density, affinity, and relative proportion of AT1 to AT2
subtypes in membranes and isolated myocytes are reported in
Table 4.
In membranes from NF hearts, the proportion of AT1 to
AT2 subtypes was 62:38 (Table 4). Total Ang II receptor and
AT1 subtype densities were significantly reduced in failing
hearts as compared with NF hearts, with no significant
differences between ICM and DCM hearts (Table 4).
Figure 2. Left, Expression of mRNAs for
AGTN, ACE, chymase, AT1, AT2, and
GAPDH and lack of renin mRNA expres-
sion in ventricular homogenates from NF
and failing hearts. Shown are representa-
tive RT-PCR experiments. Right, Bar
graphs showing changes in densitomet-
ric ratio to GAPDH.
TABLE 3. Univariate and Stepwise Multiple Regression
Between Ang II Cardiac Formation and Hemodynamic and
Echocardiographic Parameters
r P
ESS, kdyn/cm2 0.85* ,0.001
Ejection fraction, % 20.77 ,0.001
Vcf/ESS 20.75 ,0.001
LVESVI, mm/m2 0.74 ,0.001
Vcf, s21 20.72 ,0.001
Relative wall thickness, % 20.72 ,0.001
Vcf/LVEDVI 20.72 ,0.001
EDS, kdyn/cm2 0.64 ,0.001
LVEDDI, mm/m2 0.65 ,0.001
PRA, ng/mL3hour21 0.63 ,0.001
LVEDVI, mm/m2 0.62 ,0.001
LVMI, g/m2 0.55 ,0.001
ESS/LVESVI 20.49 ,0.001
LVEDP, mm Hg 0.37 ,0.01
Vcf indicates velocity of circumferential fiber shortening; LVEDDI, left
ventricular end-diastolic diameter index; LVMI, left ventricular mass index; and
LVEDP, left ventricular end-diastolic pressure.
*Independent variable at stepwise regression.
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Myocytes isolated from the left ventricle of NF hearts showed
a prevalence of the AT1 subtype (AT1:AT2579:21). AT1 and
AT2 density and affinity were unchanged in myocytes from
failing hearts as compared with NF hearts (Table 4).
Effects of Ang II Stimulation on PreproET-1
(ppET-1), IGF-I, and PDGF Synthesis
Ventricular cardiomyocytes from NF hearts expressed very
low levels of ppET-1, IGF-I, and PDGF mRNAs at quiescent
state (Figure 4). Stimulation of myocytes with Ang II (10
nmol/L) did not change GAPDH gene expression (Figure 4)
but induced a marked increase in ppET-1, IGF-I, PDGF-A,
and PDGF-B mRNAs (Figure 4).
In cardiomyocytes from NF, ICM, or DCM hearts, Ang II
failed to induce ppET-1 and IGF-I gene expression, whereas
PDGF-B and PDGF-A gene expression was comparable
among groups (Figure 4).
The assay of big ET-1, IGF-I, and PDGF-AB in the
conditioned media from stimulated cardiomyocytes con-
firmed at the peptide level the selective impairment of ET-1
and IGF-I response to Ang II stimulation (Figure 4).
Discussion
The major findings of this study may be summarized as follows:
(1) the progression of HF is associated with a progressive
increase in cardiac Ang II formation, regardless of the etiology
of the HF and with a strong correlation with the increasing ESS;
(2) the density and relative proportion of AT1 and AT2 on
isolated HF myocytes are not significantly different from those
on NF myocytes; and (3) Ang II stimulation does not induce HF
myocytes to synthesize ET-1 and IGF-I.
Increased Ang II Formation and Cardiac Function
Although the gene overexpression of ACE in dilated cardio-
myopathy was previously reported,4 the finding of a high
aorta–coronary sinus concentration gradient of both endoge-
nous angiotensins and the kinetics study of 125I-Ang I in the
present work demonstrate an increased cardiac Ang II forma-
tion in HF. Upregulation of ACE and AGTN mRNAs and the
immunohistochemical demonstration of Ang II in failing
hearts corroborate this finding. It is worth stressing that the
increased Ang II generation is independent of the HF etiol-
ogy. In failing hearts, Ang II was detectable at immunohis-
tochemistry both in myocytes and interstitial cells, whereas
AGTN and ACE mRNAs were expressed predominantly in
nonmyocytes. These findings may not be conflictual because
in situ hybridization may be unable to reveal a low increase
in mRNA expression and Ang II is uptaken by AT1 and via
endocytosis rapidly accumulated in myocytes.20 The en-
hanced Ang II generation is mainly due to the de novo Ang
I formation by cardiac tissues, despite the fact that RT-PCR
did not reveal any expression of renin mRNA in either the NF
Figure 3. A through F, In situ hybridiza-
tion for ACE (A, B, and C) and AGTN (D,
E, and F) mRNAs in left ventricular sec-
tions from NF (A and D), ICM (B and E),
and DCM (C and F) hearts. Positive
mRNA signal is revealed by red-brown
staining. In NF hearts, hybridization sig-
nals are almost absent. In failing hearts,
mRNAs are detectable mainly in intersti-
tial cells. G through I, Immunostaining for
Ang II in left ventricular sections from NF
(G), ICM (H), and DCM (I) hearts. Positive
signal revealed by red-brown staining. In
NF hearts no immunostaining for Ang II
was detected. In failing hearts immuno-
staining for Ang II was detectable in both
interstitial cells and myocytes. A through
I, Magnification 3400.
TABLE 4. Characterization of Ang II Receptors on
Cardiomyocytes and Cardiac Membranes
NF ICM DCM
Cardiomyocytes
Bmax total, fmol/mg 0.5760.21 0.5560.10 0.6060.11
Kd, nmol/L 0.1960.08 0.2160.06 0.2360.10
AT1:AT2 79;21 76;24 73;27
Bmax AT1, fmol/mg 0.4560.17 0.4160.07 0.4460.08
Bmax AT2, fmol/mg 0.1260.04 0.1460.04 0.1660.05
Cardiac membranes
Bmax total, fmol/mg 5.160.7 3.661.1* 3.460.9*
Kd, nmol/L 0.2760.08 0.2660.05 0.2560.6
AT1:AT2 62;38 58;42 47;53
Bmax AT1, fmol/mg 3.160.5 2.160.5* 1.660.5*
Bmax AT2, fmol/mg 1.960.4 1.560.5 1.860.4
*P,0.05 vs control subjects.
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or the failing hearts (Figure 2). However, the presence of
renin mRNA and its overexpression in cardiac tissues from
HF patients is not indispensable for Ang I formation, because
there is wide evidence that renin may be uptaken from plasma
by various renin binding proteins21–23 and bound to subendo-
thelium and endothelial cells.6,21 There is also evidence that
cardiac-bound renin may use the plasma AGTN present in
cardiac extracellular fluid in addition to locally synthesized
AGTN to generate Ang II.6 Therefore, the finding of in-
creased cardiac Ang I does not in any way contradict the
finding that renin mRNA was not detectable in the HF hearts.
ACE mRNA levels in myocardium from failing hearts
were higher than in NF hearts. In contrast, mRNA for
chymase, a chymostatin-sensitive serine-proteinase,7,8 was
expressed only in traces, without any significant differences
between NF and failing hearts. Thus, the present results
suggest that in failing hearts Ang II generation mainly occurs
through an ACE-dependent pathway.
Cardiac renin and plasma renin have been found to be in a
diffusional steady state in rats,24 and a positive correlation has
been reported between renin plasma levels and the renin
concentration in end-stage hearts from patients with DCM.6
In this study as well, cardiac Ang II formation was correlated
with PRA values in patients with severe HF (NYHA classes
III and IV; r50.47, P,0.001) but not in those with mild HF
(NYHA classes I and II; r50.32, NS), the majority of whom
had increased Ang II formation by cardiac tissues, although
the PRA did not differ from that of control subjects. Like-
wise, multiple-regression analysis did not select PRA as a
predictive independent variable for Ang II formation. These
findings suggest that local cardiac factor(s) are preeminent in
the activation of cardiac RAS in HF, even if important
elevation in PRA contributes to the cardiac Ang II formation.
Independently of the adjunctive role of PRA, the cardiac
generation of both angiotensins progressively increases in
relation with the impairment of cardiac function. The step-
wise regression analysis revealed the ESS as the only variable
independently correlated with Ang II formation (r50.85).
That the increase in ESS may play a major role in the
upregulation of cardiac RAS is also supported by several
studies that have shown that stretch induces Ang II formation
both by isolated myocytes25 and by beating hearts.26,27 In
patients with cardiac hypertrophy due to aortic valve disease,
cardiac Ang II formation was again enhanced only in the
patients with high ESS (.90 kdyn/cm2), regardless of the
type of overload (pressure or volume).14 The close relation-
ship between increased cardiac Ang II formation and high
ESS values is not surprising, because ESS is a sensitive
indicator of decompensation of dilated cardiomyopathy.
Thus, clinical and experimental results suggest that ESS is a
causative factor for the increase in Ang II formation in human
hearts, probably stimulating the upregulation of both ACE
and AGTN genes and facilitating the diffusion of renin from
plasma to cardiac tissues. Cardiac Ang II production was
negatively correlated with myocardial contractility as ex-
pressed not only by Vcf but also by the ESS/LVESVI ratio,
which is a sensitive contractility index independent of ven-
tricular size. However, ESS was the strongest predictor of
Ang II production, thus indicating that a mechanical factor
rather than the loss of contractility affects cardiac Ang II
production.
Myocyte and Membrane Receptor Binding Sites
Although the presence of AT1 was demonstrated using in situ
RT-PCR in both myocytes and interstitial cells,9 the density
of Ang II binding sites both in failing and NF hearts has been
studied only on cardiac homogenates. The results indicate a
general tendency of AT1 to decrease in failing hearts, with no
changes in AT2.9,10 In contrast with these studies, Tsutsumi et
al11 reported that AT2 binding sites and mRNA expression
were increased in patients with dilated cardiomyopathy. In
the present study, binding sites for Ang II receptors were
separately investigated in isolated myocytes and in myocar-
dial membranes. The results showed notable differences
between myocytes and membranes from NF hearts in the
distribution and relative proportion of the Ang II receptor
subtypes. Ang II binding sites on myocytes from NF hearts
were ’10% of the binding sites detected on ventricular
membranes, with a clear predominance of AT1s, which were
’4 times more numerous than AT2. Most importantly,
whereas binding site density for AT1 was lower on heart
membranes from failing than from NF hearts, the density of
both AT1 and AT2 on isolated myocytes from HF hearts did
Figure 4. Top, Expression of GAPDH, ppET-1, IGF-I, PDGF-A,
and PDGF-B by isolated ventricular cardiomyocytes after Ang II
stimulation (10 nmol/L); representative RT-PCR experiments are
shown. Middle, Densitometric growth factor/GAPDH mRNA
ratio. Bottom: Release of big ET-1, IGF-I and PDGF-AB in the
conditioned media from Ang II–stimulated cardiomyocytes. Data
were normalized using the peptides released by unstimulated
cells (blank subtracted). In middle and bottom panels, n indi-
cates NF; C, ICM; and v, DCM.
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not significantly differ from that of NF hearts. Thus, for the
first time we demonstrated that AT1 density is decreased on
cardiac membranes but not on myocytes from failing hearts,
and the myocytes may therefore remain in end-stage failing
hearts as potential targets for Ang II–mediated effects. The
downregulation of Ang II receptors on nonmyocyte cells
appears to be related to the HF and not to a disease-specific
mechanism, because no differences between DCM and ICM
hearts were found in the receptor density on either myocytes
or membranes. Thus, the pattern of Ang II receptors does
differ from that of ET-1 binding sites, which were increased
in ICM hearts but not in DCM ones, with a proportional
increase in ETA and ETB receptors both on myocytes and
membranes.19
The mechanisms responsible for the lack of downregula-
tion of AT1 on myocytes in comparison with nonmyocyte
cells, notwithstanding the increased Ang II, have not yet been
clarified. Mechanical stretching increases AGTN mRNA
levels and upregulates the number of AT1s and AT2s in
neonatal cultured cardiac myocytes,28–30 and this effect is
potentiated by Ang II.29 Moreover, Ang II levels were found
to be directly related to AT1 promoter activity in pressure-
overloaded myocytes.31 The combination of stretching and
Ang II might thus keep the receptor density on failing heart
myocytes similar to that of control subjects; conversely, the
lower stretching effect on the nonmyocyte cells in compari-
son with myocytes might result in a predominance of the
downregulating activity by the enhanced Ang II. Another
possibility is that the different regulation of AT1 and AT2 may
depend on differences in the regulation mechanism(s). In-
deed, a different molecular mechanism has been found to
regulate Ang II receptor subtype expression in the rat heart in
a cell- and subtype-specific manner.32 A similar mechanism
might differently regulate the gene expression of AT1 subtype
on myocytes and on nonmyocyte cells. However, specifically
addressed studies are needed to investigate the different
expression of Ang II receptor subtypes in the failing human
heart.
Incapacity of the Failing Myocytes to Synthesize
IGF-I and ET-1 and Role of Ang II in HF
The third major result in this study is the demonstration that
Ang II induces IGF-I, ET-1, and PDGF-AB synthesis by
human isolated NF myocytes and that failing myocytes are
selectively unable to produce appreciable amounts of IGF-I
and ET-1 in response to Ang II stimulation, notwithstanding
the similar density and binding capacity of Ang II receptor
subtypes. The preserved PDGF-AB generation by failing
myocytes after Ang II stimulation suggests a specific impair-
ment of the pathways leading to IGF-I and ET-1 formation
rather than a general aspecific desensitization of the Ang II
receptors. The mechanisms responsible for the incapacity of
failing myocytes to produce IGF-I and ET-1 after Ang II
stimulation remain to be investigated. Multiple signal-
transduction pathways are activated in response to AT1
stimulation,33 and many steps intervene between receptor
activation and the molecular response that increases myocyte
IGF-I and ET-1 synthesis. Thus, the defective response of
failing myocytes to Ang II stimulation may reside either in
intracellular signal transduction pathways or in transcription
factors. Specific studies are, however, necessary to investi-
gate this problem.
Cardiac IGF-I and ET-1 play a critical role in supporting
cardiac adaptive response to hemodynamic overload. Human
compensatory hypertrophy due to aortic valve disease is
associated with an increased cardiac myocyte formation of
IGF-I in volume overload and IGF-I and ET-1 in pressure
overload.14 Cardiac production of these growth factors is
positively related to myocardial contractility.14 The depres-
sion of contractility, the increase in ESS, and the progression
toward noncompensatory hypertrophy and HF are associated
with the decrease in IGF-I and ET-1 myocyte formation and
with the increase in Ang II generation.14 In experimental
pressure or volume overload in pigs, aortic banding or the
creation of an aorta-cava shunt are immediately followed by
an increased cardiac Ang II formation (within 3 hours),
leading to enhanced ET-1 and IGF-I generation by myocytes
with recovery of contractility, ESS normalization, and return
of Ang II formation to resting values within 12 hours.34 It is
important to highlight that Ang II, ET-1, and IGF-I are
synthesized by myocytes, in contrast with the incapacity of
human overloaded14 or failing myocytes to synthesize not
only ET-1 and IGF-I, but also Ang II itself, which appears to
be essentially formed by nonmyocyte cells (Reference 14 and
the present study). Thus, the increased cardiac Ang II
formation triggered by the increase in the ESS operates as an
inducing factor for the formation of IGF-I and ET-1 (and
perhaps other growth factors) by myocytes. In noncompen-
satory hypertrophy and HF, myocytes are unable to respond
to the stimulating activity of Ang II. Because AT1s on
myocytes are not downregulated in failing hearts, the long-
lasting excessive Ang II formation can mediate detrimental
effects on overloaded or failing myocytes, including depres-
sion of contractility or impaired relaxation.35 AT1s also
remain well represented on fibroblasts from failing hearts36
with consequent interstitial extracellular matrix accumula-
tion.11 Moreover, experimental evidence suggests that local
Ang II through AT1 activates the transcription factor nuclear
factor-kB,37 thereby promoting overexpression of numerous
genes, including various cytokines and adhesion molecules.
In conclusion, the present study demonstrates that early in
the clinical course of HF, cardiac Ang II formation is
increased, myocyte AT1s are not downregulated, and myo-
cytes are unable to synthesize IGF-I and ET-1 in response to
Ang II stimulation.
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